Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Metformin/Sitagliptin 850/50 mg in Healthy Volunteers
NCT05549570Phase 1Completed
- Sponsor
- Galenicum
- Start
- Oct 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sitagliptin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Galenicum. Primary endpoints: Peak Plasma Concentration at 48 hours and Area under the plasma concentration versus time curve 0-t at 48 hours. Started Oct 2017; status: completed.
02
Drugs
sitagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05549570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549570.